A Phase 2 interventional study of Bevacizumab and Cisplatin in Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 14 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-10.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.
Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 78th largest by enrollment of the 149 interventional ones that give a count, is one of 12 that started in 2007, is one of 95 in phase 2, and was the 50th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
Mabscale, LLC · Sites in Russian Federation
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 105 · Phase 3 30 · Phase 4 2
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 149 interventional studies. Of the 114 that completed or were terminated, 62 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 150 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 16 under way, 8 of them phase 3. Of 161 finished, 96 (60%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 106th largest by enrollment of the 142 interventional ones that give a count, is one of 8 that started in 2007, is one of 56 in phase 2, and was the 22nd registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
7 of the studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05654454Phase 3Mabscale, LLCA Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | 2026-12 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT06683703Beijing Biostar Pharmaceuticals Co., Ltd.Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases | 2026-12-01 |
| NCT04227028City of Hope Medical CenterBrigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | 2027-03-25 |
| NCT07453394Qilu Pharmaceutical Co., Ltd.QLS5132 Combination Therapy in Advanced Solid Tumors | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m\^2, and cisplatin 75 mg/m\^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m\^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
Drug: Bevacizumab · Drug: Cisplatin · Drug: Docetaxel
Bevacizumab was supplied as a sterile liquid in glass vials.
Also known as: Avastin
Bevacizumab was supplied as a sterile liquid in glass vials.
Bevacizumab was supplied as a sterile liquid in glass vials.
Also known as: Taxotere
Progression-free Survival
Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.
Time frame: Baseline to the end of the study (up to 4 years)
Percentage of Participants With an Objective Response
An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.
Time frame: Baseline to the end of the study (up to 4 years)
Duration of the Objective Response
Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.
Time frame: Baseline to the end of the study (up to 4 years)
Overall Survival
Overall survival is defined as the time from the first dose of study medication until death.
Time frame: Baseline to the end of the study (up to 4 years)
1-year Survival
The probability of surviving 1 year was estimated using the Kaplan-Meier method.
Time frame: Baseline to 1 year
| Milestone | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Started | 50 |
| Completed | 0 |
| Not completed | 50 |
| Withdrew: Disease progression | 23 |
| Withdrew: Adverse event | 18 |
| Withdrew: Reason not specified | 6 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal of consent | 1 |
Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.
| Months | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Progression-free Survival | 8.95 (6.92 to 9.97) |
An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.
| Percentage of participants | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Percentage of Participants With an Objective Response | 67.39 |
Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.
Results for this outcome have not been posted.
Overall survival is defined as the time from the first dose of study medication until death.
| Months | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Overall Survival | 12.74 (9.48 to 17.79) |
The probability of surviving 1 year was estimated using the Kaplan-Meier method.
| Percentage of participants | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| 1-year Survival | 53.46 (39.19 to 67.45) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Cisplatin + Docetaxel | — | 26/49 (53.1%) | 48/49 (98%) |
| Event | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Neutrophil count increasedInvestigations | 6/49 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/49 |
| PyrexiaGeneral disorders | 3/49 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 3/49 |
| Respiratory tract infectionInfections and infestations | 2/49 |
| DiarrhoeaGastrointestinal disorders | 2/49 |
| Mucosal inflammationGeneral disorders | 2/49 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/49 |
| Positron emission tomographyInvestigations | 1/49 |
| Decreased leukocyte countInvestigations | 1/49 |
| Event | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| FatigueGeneral disorders | 36/49 |
| DiarrhoeaGastrointestinal disorders | 27/49 |
| AlopeciaSkin and subcutaneous tissue disorders | 22/49 |
| Decreased hemoglobinInvestigations | 21/49 |
| Mucosal inflammationGeneral disorders | 21/49 |
| NauseaGastrointestinal disorders | 19/49 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 19/49 |
| VomitingGastrointestinal disorders | 18/49 |
| AnorexiaMetabolism and nutrition disorders | 17/49 |
| PyrexiaGeneral disorders | 15/49 |
Intent-to-treat population: All enrolled participants who received at least 1 treatment.
| Age, Continuous(Years) | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Mean | 58.31 ± 9.54 |
| Sex: Female, Male(Participants) | Bevacizumab + Cisplatin + Docetaxel |
|---|---|
| Female | 12 |
| Male | 38 |
The record gives a start of Jul 2007, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Cisplatin · Docetaxel
Carcinoma, Non-Small-Cell Lung →